Compositions and methods for treating cancer
AssigneeAlpha Beta Holdings, LLC
InventorsDavid Cheresh, Sara Weis, Stephen McCormack, Christoph Rader, Hiromi Wettersten
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric binding agents and compositions comprising the same. The invention further relates to polynucleotides encoding the chimeric binding agent and vectors and host cells comprising the same. The invention further relates to methods of using the chimeric binding agents to mediate antibody-dependent cellular cytotoxicity of epithelial cancer cells and methods of treating epithelial cell cancers.
Claims35
A chimeric binding agent comprising a first domain that specifically binds to integrin αvβ3 on an epithelial cancer cell expressing at least one mesenchymal cell marker and a second domain that mediates antibody-directed cellular cytotoxicity (ADCC) by engaging a macrophage that accumulates in mesenchymal tumors.
2-4. (canceled)
(canceled)
(canceled)
11-12. (canceled)
The chimeric binding agent of claim 12, wherein the first domain comprises the amino acid sequence of the light chain of hLM609-hIgG4-S228P (SEQ ID NO:2) or a sequence at least 90% identical thereto and the Fab portion of the heavy chain of hLM609-hIgG4-S228P (SEQ ID NO:3) or a sequence at least 90% identical thereto.
16-21. (canceled)
23-24. (canceled)
26-28. (canceled)
(canceled)
39-40. (canceled)
43-45. (canceled)
(canceled)
49-62. (canceled)
Dependencies are inferred from the claim text.